.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Citi
Colorcon
Teva
Harvard Business School
Johnson and Johnson
Medtronic
Boehringer Ingelheim
Baxter
Federal Trade Commission

Generated: December 13, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021871

« Back to Dashboard

NDA 021871 describes LOESTRIN 24 FE, which is a drug marketed by Apil and is included in one NDA. It is available from three suppliers. Additional details are available on the LOESTRIN 24 FE profile page.

The generic ingredient in LOESTRIN 24 FE is ethinyl estradiol; norethindrone acetate. There are twenty-six drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.

Summary for 021871

Tradename:1
Applicant:1
Ingredient:1
Patents:0
Formulation / Manufacturing:see details

Suppliers and Packaging for NDA: 021871

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LOESTRIN 24 FE ethinyl estradiol; norethindrone acetate TABLET;ORAL 021871 NDA Allergan, Inc. 0430-0530 0430-0530-95 30 TRAY in 1 CASE (0430-0530-95) > 6 CARTON in 1 TRAY > 1 POUCH in 1 CARTON > 1 BLISTER PACK in 1 POUCH > 1 KIT in 1 BLISTER PACK
LOESTRIN 24 FE ethinyl estradiol; norethindrone acetate TABLET;ORAL 021871 NDA Allergan, Inc. 0430-0530 0430-0530-14 72 CARTON in 1 CASE (0430-0530-14) > 5 POUCH in 1 CARTON > 1 BLISTER PACK in 1 POUCH > 1 KIT in 1 BLISTER PACK

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength0.02MG;1MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Feb 17, 2006TE:ABRLD:Yes

Expired Orange Book Patents for NDA: 021871

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
ApilLOESTRIN 24 FEethinyl estradiol; norethindrone acetateTABLET;ORAL021871-001Feb 17, 2006► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Citi
Moodys
Cerilliant
Medtronic
Accenture
AstraZeneca
Fish and Richardson
Covington
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot